Since we became effected by Coronavirus, medical experts have been talking about a vaccine.
Yesterday, Moderna and the National Institute of Allergy and Infectious Diseases entered Phase 3 of their clinical trial of a Covid-19 vaccine here in the United States. These two groups are part of the National Institutes of Health.
Approximately 30,000 adults are expected to sign up voluntarily to take part in the study. Phase three increases not only the amount of participants, but also takes note of the desired effectiveness of the vaccine as well as the safety of the immunization and potential side effects after two doses. The Moderna/NIH vaccine is then checked for the overall effectiveness against Covid-19 and its symptoms.
Phase 1 trial results were positive earlier this month and the results were published in the prestigious New England Journal of Medicine.
The Journal found it induced immune responses in every volunteer participant, as well as being generally safe, with only minor side effects such as fatigue, chills, headaches, muscle pain and pain at the injection site, which is quite common for most immunizations.
Phase 1 normally includes a smaller test group and focuses on whether the vaccine is safe and produces immune response to the respective flu or virus in question. When the study moves on to Phase 2, it is expanded and subjects are individuals who fit the criteria of individuals generally affected by the flu, virus, or infection being studied, such as age and physical health.
However, that’s not all…there’s MORE good news. This isn’t by any stretch the only study in motion currently. It is only one of 25 known vaccines being tested to combat Covid-19 worldwide according to the World Health Organization.
It’s also being reported that the first volunteers for another large scale trial for a Covid vaccine being developed by Pfizer and BioNTech is also underway.